NHS Blood and Transplant

Board Meeting in Public

Tuesday, 01 December 2026

Title of Paper	Financial Performance Report	**Agenda No.**	3.3
Nature of Paper	☐ Official	☒ Official Sensitive	
Author(s)	Mark Taylor – Assistant Finance Director Planning and Performance		
Lead Executive	Sarah Stansfield – Chief Financial Officer		
Non-Executive Director Sponsor	Ian Murphy		
Presenter(s) at Meeting	Sarah Stansfield – Chief Financial Officer		
Presented for	☐ Approval ☐ Information ☒ Assurance ☒ Update		
Is there a plan to communicate this to the organisation?	☐ Yes ☒ No ☐ Yet to be determined		

Executive Summary

- NHSBT is forecasting a year-end deficit of £24m, £1m adverse to the planned deficit of £23m.
- Operational performance remains broadly in line with plan. However, long-term financial sustainability remains dependent on addressing an estimated £11m CIP non recurrent shortfall, currently going to be carried forward into 2027/28.
- The forecast includes a £20m risk adjustment applied since Q2 to reflect identified financial risks. Should these risks not materialise, the year-end position would be reinstated accordingly
- Current performance continues to benefit from non-recurrent items, including transformation programme underspends and released budget contingencies.
- Capital expenditure is forecast is expected to remain close to the £35m DHSC allocation. NHSBT continues to work closely with DHSC to confirm the final capital drawdown requirement as part of APM08 reporting

Previously Considered by

ET – Tuesday 17th November

Recommendation

- To note: Forecast is broadly aligned with budget, but includes a £20m prudent risk adjustment
- To note: Up to £11m of the £24.6m CIP target is currently non-recurrent and must now be converted to recurrent savings to avoid a financial pressure recurring in 2027/28.
- To note: NHSBT to confirm the CDEL final drawdown before Christmas, enabling any surplus funding to be redeployed across the system or applied to wider financial pressures.

Risk(s) identified (Link to Board Assurance Framework Risks)

There is a risk of material constraints to the delivery of NHSBT's critical products/services, caused by a failure to maintain financial sustainability, resulting in patients' health and wellbeing being put at risk and a loss of public and stakeholder confidence

Strategic Objective(s) this paper relates to:

☒ Modernising One NHSBT ☒ Optimising Donor Experience and Meeting Demand
☒ Campaigning & Identity ☒ Data, AI and Interoperability ☒ New Treatments

Appendices:	